Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resul...

by Louise Hiller, Janet A. Dunn, Shrushma Loi, Anne-Laure Vallier, Donna L. Howe, David A. Cameron, David Miles, Andrew M. Wardley, Helena M. Earl
Published 2018-04-01